Dr. Agarwal's Health Care cash flow

Latest FY26
Cash from operations
₹519cr+44.0% on FY25
Capital spending
₹461cr+43.5% on FY25
Free cash flow
₹58.4cr+48.1% on FY25
Cash from financing
−₹220cr₹382 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
Adjustments to reconcile profit — non-cash items
—276231
—0.03.0
—70.079.8
—−11.3−7.3
—−1.3−2.0
—7.48.4
—12.62.0
—−0.63.5
—−14.413.3
—35.60.0
Changes in working capital
—−13.8−26.5
—−54.1−43.6
—−17.1−31.2
—0.0−16.1
—−4.5−8.5
—0.8−3.9
—0.026.6
—28.50.0
—0.0−0.7
—12.45.2
—0.04.4
Cash from operating activities
270249160
—326237
—575397
—−0.90.0
—55.136.6
—519360
Cash from investing activities
—448309
—12.612.3
—0.90.5
—6.30.0
—85.1516
—5.33.4
—23782.5
—−308−750
Cash from financing activities
—11.4655
—0.061.5
—89.6203
—13399.0
—7.932.2
—1.10.8
—−220382
—−9.9−8.1
—−9.9−8.1
——104
Reference items
612570456
27.7%27.4%26.7%
58.458.439.4
—−39.1—
₹1.84₹1.84₹1.24
265.06×——
—3.09×3.27×
—55.136.6
—7.932.2
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AGARWALEYE₹488.70

Dr. Agarwal's Health Care Ltd.

· Pharma & Health
₹ CrorePeersAKUMSADVENZYMESALIVUSAARTIPHARMAARTIDRUGSAPLLTDCORONAHCGMcap ₹15,482 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation230.7276.2—
+ Impairment Loss / (Reversal)3.00.0—
+ Finance Costs79.870.0—
+ Interest Income-7.3-11.3—
+ Fair Value (Gains) / Losses-2.0-1.3—
+ Share-based Payments8.47.4—
+ Unrealised FX (Gain) / Loss2.012.6—
+ Other Non-cash Items3.5-0.6—
+ Other — Cash Effects are Investing / Financing13.3-14.4—
+ Other Reconciling Items0.035.6—
Changes in Working Capital
+ Inventories-26.5-13.8—
+ Trade Receivables — Current-43.6-54.1—
+ Other Financial Assets — Current-31.2-17.1—
+ Other Financial Assets — Non-current-16.10.0—
+ Other Current Assets-8.5-4.5—
+ Other Non-current Assets-3.90.8—
+ Trade Payables — Current26.60.0—
+ Other Financial Liabilities — Current0.028.5—
+ Other Financial Liabilities — Non-current-0.70.0—
+ Other Current Liabilities5.212.4—
+ Provisions — Current4.40.0—
Cash from Operating Activities
Profit Before Tax (per I/S)159.9248.6270.2
+ Total Adjustments (incl. Working Capital)237.1326.3—
Cash from Operations (pre-tax)396.9575.0—
+ Interest Received — Operating0.0-0.9—
+ Income Taxes Paid36.655.1—
Cash from Operating Activities360.3519.0—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)308.6448.0—
+ Acq of Intangible Assets12.312.6—
+ Disp of Fixed Assets0.50.9—
+ Purchase of Investments (Equity / Debt)0.06.3—
+ Acq of Subsidiaries / Businesses (net)515.885.1—
+ Interest Received — Investing3.45.3—
+ Other Inflows / (Outflows) — Investing82.5237.4—
Cash from Investing Activities-750.3-308.5—
Cash from Financing Activities
+ Proceeds from Issue of Shares654.911.4—
+ Proceeds from Borrowings61.50.0—
+ Repayment of Borrowings202.689.6—
+ Payment of Lease Liabilities99.0133.2—
+ Interest Paid32.27.9—
+ Dividends Paid0.81.1—
Cash from Financing Activities381.9-220.4—
Net Changes in Cash (pre-FX)-8.1-9.9—
Net Changes in Cash-8.1-9.9—
Closing Cash103.6——
Reference Items
EBITDA456.4569.6612.1
EBITDA Margin %26.6727.3827.74
Free Cash Flow (CFO − Capex)39.458.458.4
Free Cash Flow to Equity—-39.1—
Free Cash Flow per Basic Share1.241.841.84
Price to Free Cash Flow——265.06
Cash Flow to Net Income3.273.09—
Cash Paid for Taxes36.655.1—
Cash Paid for Interest32.27.9—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.